Tiagabine as add-on therapy may be more effective with valproic acid - Open label, multicentre study of patients with focal epilepsy

European Journal of Neurology

Volumn 12, Issue 3, 2005, Pages 176-180

  Jȩdrzejczak, Joanna ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Determinants of efficacy; Focal epilepsies; Tiagabine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADULT; AGED; CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; EPILEPTIC STATE; EVALUATION; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOMES RESEARCH; POLAND; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SEIZURE; SOMNOLENCE; TITRIMETRY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NIPECOTIC ACIDS; POLAND; SEIZURES; SEX FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 14044275666     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00874.x     Document Type: Review

References (15)

1. Bauer J, Bergmann A, Reuber M, Stodieck SR, Genton P (2002). Tolerability of tiagabine: a prospective open-label study. Epileptic Disord 4:257-260.
2. Ben-Menachem E (1995). International experience with tiagabine add-on therapy. Epilepsia 36 (Suppl. 6): 14-21.
3. Buttery PC, Sisodiya SM (2002). The safety, tolerability and adverse events profile of tiagabine. Rev Contemp Pharmacother 12:251-264.
4. Casas-Fernandez C, Domingo-Jimenez R (2002). Characteristics and indications of tiagabine. Rev Neurol 35 (Suppl. 1):96-100.
5. Commission on Classification and Terminology of International League Against Epilepsy (1989). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389-399.
6. Covanis A, Giannakodimos S, Spilioti M et al. (2001). Tiagabine adjunctive therapy in children and adults with refractory partial epilepsy. Epilepsia 42 (Suppl. 2):147.
7. Gaitatzis A, Patsalos PN, Sander JW (2002). The clinical efficacy of tiagabine. Rev Contemp Pharmacother 12:235-250.
8. Gustavson LE, Cato A III, Boellner SW et al. (1998). Lack of pharmacokinetic drug interaction between tiagabine and carbamazepine or phenytoin. Am J Ther 5:9-16.
9. Hirsch E, de Saint-Martin A, Arzimanoghou A (2000). New insights into the clinical management of partial epilepsies. Epilepsia 41 (Suppl. 5):13-17.
10. Kozik A, Krause M (2003). Determinants of tiagabine (TGB) efficacy and safety. A Polish multi-center study of 1037 patients with focal epilepsy. Neurol Neurochir Pol 37:553-562.
11. Łuszczki J, Świader M, Czuczwar M, Kis J, Czuczwar SJ (2003). Inreactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol Biochem Behav 75:319-327.
12. Mattson RH (1995). Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 36 (Suppl. 2): 13-26.
13. Pereira J, Marson AG, Mutton JL (2002). Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3:CD001908.
14. Schmidt D, Gram L, Brodie M et al. (2000). Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician. Epilepsy Res 41:245-251.
15. Walker MC, Sander JW (1997). Difficulties in extrapolating from clinical trials data to clinical practice: the case of antiepileptic drugs. Neurology 49:333-337.